<DOC>
	<DOCNO>NCT00194675</DOCNO>
	<brief_summary>The purpose research study determine whether combination male hormone testosterone [ T ] gel form oral drug dutasteride [ D ] , use shrink large prostate gland safely reduce size prostate gland symptom prostate enlargement ( call benign prostatic hyperplasia [ BPH ] ) compare T treatment alone men low testosterone ( call hypogonadism ) .</brief_summary>
	<brief_title>TRADE-Testosterone Replacement Dutasteride Effectiveness</brief_title>
	<detailed_description>The primary aim study determine whether correction hypogonadism use combination testosterone dutasteride spar subject increase prostate size symptom BPH may associate T alone . We also determine effect change serum T dihydrotestosterone ( DHT ) hormonal milieu genetic program within prostate gland . The technology employ allow u determine gene androgen responsive within prostate tissue compartment . Together , data may determine whether combination testosterone dutasteride safely correct symptom BPH hypogonadism minimize growth stimulus prostate genetic level . We also assess effect combination T dutasteride cognitive function . This six-month , double-blind , randomize , placebo-controlled , single-site study old hypogonadal men mild moderate BPH . Within treatment group , sub-group subject undergo additional procedure part Prostate Biopsy sub-study obtain prostate tissue hormonal genetic analysis . Selection subject base clinical indication and/or willingness undergo prostate biopsy .</detailed_description>
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<mesh_term>Hypogonadism</mesh_term>
	<mesh_term>Dutasteride</mesh_term>
	<mesh_term>Testosterone</mesh_term>
	<mesh_term>Testosterone enanthate</mesh_term>
	<mesh_term>Testosterone undecanoate</mesh_term>
	<mesh_term>Testosterone 17 beta-cypionate</mesh_term>
	<mesh_term>Methyltestosterone</mesh_term>
	<criteria>Generally healthy old men 50 year old old Hypogonadism ; low testosterone ( total T le 280 ng/dL one occasion average equal le 300 ng/dl two occasion ) Prostate volume equal 30 cc prostate MRI Prostate Specific Antigen ( PSA ) equal 1.5 ng/mL equal less 10 ng/mL Subjects PSA great 4.0 ng/ml must negative prostate biopsy International Prostate Symptom Score ( IPSS ) great equal 8 less equal 20 screen Comply study procedure full 10 month No contraindication MRI Subjects symptomatic Benign Prostatic Hyperplasia ( BPH ) recruit Urology General Internal Medicine Clinics VA Puget Sound Health Care System University Washington Medical Center Seattle . A history prostate breast cancer Invasive therapy BPH past History acute urinary retention 3 month prior screen Previous treatment 5 alphareductase inhibitor ( finasteride dutasteride ) Medical therapy BPH within past month ( alphablocker , phytotherapy ) Use androgenic antiandrogenic drug past year History evidence prostate cancer include suspicious DRE history highgrade PIN prostate biopsy . Severe systemic illness ( renal , liver , cardiac , lung disease , cancer , diabetes ) Known untreated obstructive sleep apnea Hematocrit great 52 Severe skin disease may interfere testosterone gel absorption Hypersensitivity drug use study History bleed disorder need chronic anticoagulation Participation drug study concurrently last 90 day History current evidence drug alcohol abuse within 12 mo . Weight 300 lb .</criteria>
	<gender>Male</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>androgen deficiency</keyword>
	<keyword>testosterone</keyword>
	<keyword>Benign Prostatic Hyperplasia</keyword>
	<keyword>hypogonadism</keyword>
	<keyword>prostate</keyword>
	<keyword>BPH</keyword>
</DOC>